Publications (2)0 Total impact
Article: A molecular adsorbent recycling system in treating posthepatectomy acute hepatic failure patients with hepatocellular carcinoma: a bridge to liver transplantation[show abstract] [hide abstract]
ABSTRACT: OBJECTIVE To evaluate the effect and safety of a Molecular Adsorbent Recycling System (MARS) in treating posthepatoectomy hepatic failure (AHF) patients surgically treated for primary hepatocellular carcinoma (HCC). METHODS 12 AHF patients induced by resection of HCC were treated with MARS before orthotopic liver transplantation (OLT). Their vital signs, urine volume, APACHEIII and Glasgow scores were monitored. Routine laboratory blood tests, measurements of coagulatory function, liver and kidney function, serum ammonia, lactic acid and blood gas were conducted before and after treatment with MARS. All of the patients were followed up for a period of 6 months after OLT for prognosis and complication assessment. RESULTS Each patient was treated with MARS for 2–5 times (average of 3.6) with a length of 8–24 h each time. Their mean arterial blood pressure and urine volume were improved, APACHE III and Glasgow scores were better. Liver function was improved with the following alterations before and after treatment with MARS: serum ammonia (127.1±21.4 umol/L vs. 77.4±19.7 umol/L, P<0.05), lactic acid (6.53±0.45 mmol/L vs. 3.75±0.40 mmol/L, P<0.05) and total bilirubin (452.3±153.7 umol/L vs. 230.9±115.2 umol/L, P<0.05). However, there was no significant change in platelet count (44.25±3.60×109/L vs. 43.19±8.26×109/L, P>0.05) on international normalized ratio (INR) (2.74±0.50 vs. 2.82±0.60, P>0.05), which showed the safety of MARS. For all patients no serious adverse effects occurred during the treatment with MARS. CONCLUSION MARS is effective and safe for treatment of AHF patients with HCC, especially as a bridge to OLT when a donor organ is not available.Chinese Journal of Clinical Oncology 07/2006; 3(4):273-276.
[show abstract] [hide abstract]
ABSTRACT: Liver transplantation has expanded rapidly in China. The Tianjin First Central hospital is currently the largest liver transplant center in China. During 2005, this center performed 647 liver transplants and 436 kidney transplants. Since the liver transplantation program began in 1998, this center has performed 1,803 liver transplants and 1,233 kidney transplants. Significant progress has been made during the past 5 years in surgical technique, immunosuppression and patient care after transplantation. Graft survival rates have also improved significantly. The one-year graft survival rate for 843 patients who received a liver transplant between 2001 and 2004 was 87.3%. About half of these patients suffered from hepatocellular carcinoma. We will continue to evaluate donor and recipient factors to maximize outcomes of liver and kidney transplantation.Clinical transplants 01/2005;